Mustang Bio Inc. (MBIO) Financial Statements (2026 and earlier)

Company Profile

Business Address 95 SAWYER RD
WALTHAM, MA 02453
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17,266,00018,984,00012,657,00014,231,0006,839,0003,525,000
Cash and cash equivalent17,266,00018,984,00012,657,00014,231,0006,839,0003,525,000
Receivables217,000     
Asset, held-for-sale, not part of disposal group     1,165,0002,209,000
Other undisclosed current assets 110,000377,000389,000678,000602,000321,000
Total current assets:17,593,00019,361,00013,046,00014,909,0008,606,0006,055,000
Noncurrent Assets
Operating lease, right-of-use asset     81,00092,000
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization     371,000421,000
Restricted cash and investments      375,000
Other noncurrent assets     250,000250,000
Total noncurrent assets:     702,0001,138,000
Other undisclosed assets      
TOTAL ASSETS:17,593,00019,361,00013,046,00014,909,0009,308,0007,193,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5,411,0006,911,0007,500,0008,337,0009,486,00012,061,000
Accounts payable3,510,0004,993,0005,650,0006,309,0007,464,0008,759,000
Other undisclosed accounts payable and accrued liabilities1,901,0001,918,0001,850,0002,028,0002,022,0003,302,000
Other liabilities2,503,0002,529,0002,504,0002,813,0002,667,0002,535,000
Other undisclosed current liabilities     456,000442,000
Total current liabilities:7,914,0009,440,00010,004,00011,150,00012,609,00015,038,000
Noncurrent Liabilities
Liabilities, other than long-term debt150,000150,000150,000150,000572,000811,000
Deferred revenue150,000150,000150,000150,000150,000270,000
Operating lease, liability     422,000541,000
Total noncurrent liabilities:150,000150,000150,000150,000572,000811,000
Total liabilities:8,064,0009,590,00010,154,00011,300,00013,181,00015,849,000
Equity
Equity, attributable to parent, including:9,529,0009,771,0002,892,0003,609,000(3,873,000)(8,656,000)
Common stock, value, subscriptions 273,000   611,000 
Additional paid in capital407,899,000407,876,000400,530,000400,485,000392,234,000387,112,000
Accumulated deficit(398,644,000)(398,106,000)(397,638,000)(396,876,000)(396,723,000)(395,771,000)
Other undisclosed equity, attributable to parent1,0001,000  5,0003,000
Total equity:9,529,0009,771,0002,892,0003,609,000(3,873,000)(8,656,000)
TOTAL LIABILITIES AND EQUITY:17,593,00019,361,00013,046,00014,909,0009,308,0007,193,000

Income Statement (P&L) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Operating expenses(670,000)(624,000)(885,000)(253,000)(1,017,000)(1,457,000)
Operating loss:(670,000)(624,000)(885,000)(253,000)(1,017,000)(1,457,000)
Nonoperating income132,000156,000123,000100,00065,00047,000
Interest and debt expense     (1,000)(1,000)
Loss from continuing operations before income taxes:(538,000)(468,000)(762,000)(153,000)(953,000)(1,411,000)
Other undisclosed loss from continuing operations (27,000)     
Net loss:(565,000)(468,000)(762,000)(153,000)(953,000)(1,411,000)
Other undisclosed net income attributable to parent 27,000   1,0001,000
Net loss available to common stockholders, diluted:(538,000)(468,000)(762,000)(153,000)(952,000)(1,410,000)

Comprehensive Income (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(565,000)(468,000)(762,000)(153,000)(953,000)(1,411,000)
Comprehensive loss, net of tax, attributable to parent:(565,000)(468,000)(762,000)(153,000)(953,000)(1,411,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: